Project description:This dataset investigates the transcriptional effect of mitochondrial 12S rRNA hypermethylation, both by overexpressing the mitochondrial methyltransferase mtTFB1 in HeLa cells and by using A1555G cybrids, where the 12S rRNA is hypermethylated. HeLa cells overexpressing a methyltransferase-deficient mtTFB1 (mtTFB1[G65A]) and wild-type A1555A cybrids were used as controls. four samples with 12S rRNA hypermethylation (two cell lines, with two biological replicates each) versus four samples with basal 12S rRNA methylation (two cell lines, with two biological replicates each)
Project description:This dataset investigates the transcriptional effect of mitochondrial 12S rRNA hypermethylation, both by overexpressing the mitochondrial methyltransferase mtTFB1 in HeLa cells and by using A1555G cybrids, where the 12S rRNA is hypermethylated. HeLa cells overexpressing a methyltransferase-deficient mtTFB1 (mtTFB1[G65A]) and wild-type A1555A cybrids were used as controls.
Project description:In this project, we developed electrophoresis-correlative (Eco) data-independent acquisition (DIA) mass spectrometry (MS). We recognized a correlation between the measured mass-to-charge (m/z) and migration time (MT) for peptides during capillary electrophoresis (CE) electrospray ionization (ESI) MS. We leveraged this relationship to dynamically tailor the experimental settings of DIA on an orbitrap mass spectrometer. This approach substantially improved utilization of the limited duty cycle during tandem MS and detection sensitivity compared to the classical DIA. From 1 ng of the standard HeLa proteome digest, Eco-DIA identified ~38% more proteins than conventional DIA, without the assistance of a project-specific spectral library. Proteins that were quantified exclusively by Eco-DIA were in the lower abundance range. Eco-DIA improved the sensitivity of detection from limited amounts of proteomes using CE-ESI-MS.
Project description:The purpose of this study was to determine the maximum tolerated dose (MTD) and the recommended dose for future studies of ECO-4601 administered as a continuous IV infusion for 14 days with 7 days recovery (21 day cycle) in patients with histologically confirmed solid tumors (high grade glioma, colorectal, lung, breast, ovarian, pancreatic and prostate). This study was also designed to determine the clinical pharmacokinetic profile, safety of multiple cycles of administration, and document the antitumor activity of ECO-4601.